The global aging population is reshaping healthcare investment opportunities, with the geriatric care services market projected to grow from $1.24 trillion in 2025 to $2.16 trillion by 2034. Healthcare companies are capitalizing on this demographic shift through innovations in diabetes care, cardiovascular treatments, robotic surgery, and digital health solutions. Key players like AbbVie, Tandem Diabetes Care, Amgen, Stryker, and Boston Scientific are advancing AI-enabled technologies and specialized treatments for age-related conditions.

Zacks has added three stocks to its Strong Sell list today: AngloGold Ashanti (gold mining), Aptiv PLC (industrial technology), and Boston Scientific Corporation (medical devices). All three companies have experienced downward revisions to their current year earnings estimates over the last 60 days, with Aptiv seeing the largest revision at 10.1% downward.

The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.

The global Intravascular Lithotripsy (IVL) market is projected to grow from USD 1.01 billion in 2025 to USD 4.19 billion by 2035, expanding at a 15.3% CAGR. Growth is driven by increasing prevalence of calcified coronary and peripheral artery disease, adoption of minimally invasive procedures, and expanding peripheral IVL applications. North America leads with 58% market share, while Asia-Pacific is the fastest-growing region.

Boston Scientific CEO Michael F. Mahoney purchased approximately 208,000 shares worth $10.1 million on August 3, 2026, at a weighted average price of $48.34 per share, expanding his equity stake by 13%. The purchase signals confidence in the company's future despite a -54% one-year stock decline, as the company benefits from recent acquisitions bolstering its product pipeline for 2027-2029 and a $500 million cost-cutting restructuring initiative.

Ceribell announced the appointment of Thomas West and Sharon O'Keefe to its Board of Directors. West, former CEO of Nalu Medical (acquired by Boston Scientific for $600M) and Intersect ENT (acquired by Medtronic for $1.1B), and O'Keefe, former President of University of Chicago Medical Center, bring significant commercial and health-system leadership experience. The appointments support Ceribell's expansion as its point-of-care brain monitoring platform is now deployed in over 680 U.S. hospitals.

Implicity announced FDA 510(k) clearance for its next-generation ILR ECG Analyzer, a cloud-based AI software that reduces false-positive alerts from implantable cardiac monitors by up to 76% while maintaining high sensitivity. The manufacturer-agnostic algorithm works with devices from Abbott, Biotronik, Boston Scientific, and Medtronic, addressing a significant clinical workflow burden in remote cardiac monitoring.

The global electrosurgery market is projected to grow from $8.01 billion in 2025 to $11.59 billion by 2031, with a CAGR of 6.4%. Growth is driven by increasing surgical volumes, rising chronic disease prevalence, and adoption of minimally invasive procedures. However, challenges include procedural risks, regulatory constraints, and surgeon shortages. Ambulatory surgical centers are expanding their role, while the United States leads North American growth.

The global robotic endoscopy devices market is projected to grow from USD 2.8 billion in 2025 to USD 6.5 billion by 2034, driven by increasing demand for minimally invasive procedures, technological advancements in AI-enabled navigation and imaging, and rising prevalence of gastrointestinal disorders. North America leads the market with 42% share, while Asia-Pacific is expected to witness the highest growth. Key players include Intuitive Surgical, Medtronic, Johnson & Johnson MedTech, and others.

The global urology devices market is valued at USD 39.23 billion in 2025 and is projected to reach USD 80.0 billion by 2035, growing at a CAGR of 7.35%. Growth is driven by rising demand for robotic-assisted surgery, kidney disease treatment, and minimally invasive procedures. North America leads the market while Asia Pacific records the fastest growth.

The global disposable endoscopes market is expected to expand at a CAGR of 15.04% through 2035, driven by rising infection prevention initiatives, adoption of single-use endoscopes, and minimally invasive procedures. North America leads with 38.45% market share, while Asia Pacific records the fastest growth. Hospitals dominate the end-user segment with 55.36% market share, with ambulatory surgical centers showing the highest growth potential.

The global brain implants market, valued at USD 7.10 billion in 2025, is projected to reach USD 18.39 billion by 2035, growing at a CAGR of 9.99%. Growth is driven by rising prevalence of neurological disorders and increasing adoption of deep brain stimulation, neuromodulation systems, and brain-computer interfaces. North America leads the market, with the U.S. expected to grow from USD 3.16 billion to USD 8.17 billion by 2035.